#1 Clinical Trials Search in Europe

Paclitaxel

This article explores the use of paclitaxel, particularly in its albumin-bound form known as Abraxane, in various clinical trials for cancer treatment. Paclitaxel is a chemotherapy drug that has shown promise in treating several types of cancer, including breast, bladder, head and neck, and melanoma. The trials discussed here aim to evaluate the efficacy, safety, and potential new applications of paclitaxel in different cancer types and treatment regimens.

Table of Contents

What is Paclitaxel?

Paclitaxel is a powerful chemotherapy drug used to treat various types of cancer. It’s also known by its brand names Taxol® and Onxal[1]. Paclitaxel belongs to a class of drugs called taxanes, which are derived from the bark of the Pacific yew tree.

What Conditions Does Paclitaxel Treat?

Paclitaxel is used to treat several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): Paclitaxel is used in combination with other drugs to treat advanced stages of this type of lung cancer[2].
  • Breast cancer: It’s used in various stages of breast cancer, including metastatic (cancer that has spread to other parts of the body) and triple-negative breast cancer[3][4].
  • Gastric (stomach) cancer: Paclitaxel is used in combination therapies for advanced gastric cancer[5].
  • Ovarian cancer: Although not specifically mentioned in the provided trials, paclitaxel is commonly used to treat ovarian cancer.

How Does Paclitaxel Work?

Paclitaxel works by interfering with the growth of cancer cells, slowing their spread in the body. Specifically, it:

  • Stops cancer cells from dividing by stabilizing microtubules (structures within cells that are crucial for cell division)
  • Causes cancer cells to die, a process known as apoptosis

How is Paclitaxel Administered?

Paclitaxel is typically administered in the following ways:

  • Intravenous (IV) infusion: The drug is given through a vein, usually over a period of 30-60 minutes[4].
  • Dosage: The dose can vary, but common dosages include 80 mg/m² weekly or 175 mg/m² every three weeks[4][6].
  • Treatment cycles: Paclitaxel is often given in cycles, with periods of treatment followed by periods of rest.

Paclitaxel in Combination Therapies

Paclitaxel is frequently used in combination with other drugs to enhance its effectiveness. Some common combinations include:

  • Paclitaxel + Carboplatin: This combination is used in treating non-small cell lung cancer and ovarian cancer[2].
  • Paclitaxel + Trastuzumab (Herceptin®): Used in HER2-positive metastatic breast cancer[4].
  • Paclitaxel + Bevacizumab: This combination is being studied in non-small cell lung cancer[7].
  • Paclitaxel + Onvansertib: Being studied for triple-negative breast cancer[3].

Potential Side Effects

Like all chemotherapy drugs, paclitaxel can cause side effects. Some common side effects may include:

  • Low blood cell counts (which can increase risk of infection and bleeding)
  • Hair loss
  • Nausea and vomiting
  • Muscle and joint pain
  • Numbness or tingling in hands and feet (neuropathy)

Your healthcare team will monitor you closely for these and other side effects during treatment.

Ongoing Research and Clinical Trials

Researchers continue to study paclitaxel to find new ways to use it effectively. Some areas of ongoing research include:

  • New formulations: A form of paclitaxel called nab-paclitaxel (also known as Abraxane) is being studied in various cancers. This formulation binds paclitaxel to albumin, a protein in human blood, which may help deliver more of the drug to cancer cells[2][8].
  • Combination therapies: Researchers are studying paclitaxel in combination with newer drugs to improve its effectiveness[3][7].
  • Metronomic chemotherapy: This approach involves giving lower doses of chemotherapy drugs more frequently. A study is looking at this approach using paclitaxel and other drugs in triple-negative breast cancer[6].
  • New delivery methods: A drug called ONCOFID-P-B, which combines paclitaxel with hyaluronic acid, is being studied for bladder cancer. This formulation allows the drug to be given directly into the bladder[9][10].

These ongoing studies aim to improve the effectiveness of paclitaxel while minimizing its side effects, potentially benefiting more patients in the future.

Cancer Type Trial Focus Key Findings/Objectives
Urothelial Cancer Combination therapy with ABI-007, carboplatin, and gemcitabine Evaluating safety and efficacy in advanced bladder cancer
Metastatic Melanoma Comparison of Abraxane with and without CC-486 Assessing overall survival, tumor response, and progression-free survival
Colorectal and Small Bowel Cancer Single-agent Abraxane in CIMP-High tumors Evaluating response rate and progression-free survival
Head and Neck Cancer Abraxane with addition of Cetuximab on disease progression Assessing overall response rate and toxicity profile
Breast Cancer Neoadjuvant chemotherapy with Abraxane vs. common paclitaxel Comparing pathological complete remission rates
Bladder Cancer Intravesical Abraxane for treatment-refractory cases Determining safety, toxicity, and efficacy profiles
Triple Negative Breast Cancer Abraxane with or without Tigatuzumab Evaluating objective response rate and progression-free survival

FAQ

  • What is Abraxane? Abraxane is an albumin-bound form of paclitaxel, a chemotherapy drug. It is designed to deliver paclitaxel more effectively to cancer cells and may have fewer side effects compared to traditional paclitaxel formulations.
  • What types of cancer are being studied with Abraxane? Clinical trials are exploring the use of Abraxane in various cancers, including breast cancer, bladder cancer, head and neck cancer, melanoma, and urothelial cancer.
  • How is Abraxane administered in these trials? Abraxane is typically administered intravenously, with dosages and schedules varying depending on the specific trial and cancer type. Some trials are also exploring intravesical administration for bladder cancer.
  • What are the potential benefits of using Abraxane? Potential benefits include improved efficacy in treating certain cancers, reduced side effects compared to traditional paclitaxel formulations, and the ability to deliver higher doses of the drug to cancer cells.
  • Are there any unique approaches being tested with Abraxane? Yes, some trials are combining Abraxane with other drugs like cetuximab or tigatuzumab to enhance its effectiveness. Others are exploring its use in neoadjuvant chemotherapy or comparing it to standard paclitaxel formulations.

Ongoing Clinical Trials on Paclitaxel

  • Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +9

  • Phase III Randomized Study of Rilvegostomig vs. Pembrolizumab with Platinum-based Chemotherapy in PD-L1 Expressing Metastatic Squamous NSCLC

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium France Germany Hungary Italy +3

  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy

  • Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Germany Italy Norway

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • Study of patritumab deruxtecan versus drug combination in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Hungary Italy Poland +1

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +2

  • Maintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer

    Recruiting

    3 1 1
    Investigated drugs:
    Belgium Finland France Germany Italy Poland +1

  • Comparing AZD5335 with Mirvetuximab Soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Denmark France Germany Greece +4

  • A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark Finland France Germany Greece +5

Glossary

  • Abraxane: An albumin-bound form of paclitaxel, designed to deliver the chemotherapy drug more effectively to cancer cells.
  • Neoadjuvant chemotherapy: Chemotherapy given before surgery to shrink tumors and potentially improve surgical outcomes.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Triple-negative breast cancer: A type of breast cancer that lacks estrogen receptors, progesterone receptors, and HER2 protein, making it more difficult to treat.
  • Intravesical therapy: Treatment administered directly into the bladder through a catheter.
  • Progression-free survival: The length of time during and after treatment that a patient lives without the cancer progressing.
  • Overall survival: The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate: The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Dose-limiting toxicity: Side effects severe enough to prevent an increase in the dose of a drug being tested in a clinical trial.

References

  1. https://clinicaltrials.gov/study/NCT04166487
  2. https://clinicaltrials.gov/study/NCT01757288
  3. https://clinicaltrials.gov/study/NCT05383196
  4. https://clinicaltrials.gov/study/NCT01989676
  5. https://clinicaltrials.gov/study/NCT00154778
  6. https://clinicaltrials.gov/study/NCT00542191
  7. https://clinicaltrials.gov/study/NCT04325698
  8. https://clinicaltrials.gov/study/NCT02486601
  9. https://clinicaltrials.gov/study/NCT04798703
  10. https://clinicaltrials.eu/trial/study-of-oncofid-p-b-for-patients-with-bladder-carcinoma-in-situ-unresponsive-to-bcg-treatment/